The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study.
 
Grant A. McArthur
Research Funding - Genentech/Roche (Inst); MSD (Inst); Roche (Inst)
 
Ralf Gutzmer
Honoraria - Almirall Hermal GmbH; Amgen; Bristol-Myers Squibb; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron; Sun Pharma
Consulting or Advisory Role - 4SC; Almirall Hermal GmbH; Amgen; Bristol-Myers Squibb; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi; Sun Pharma
Research Funding - Amgen (Inst); Johnson & Johnson (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Sun Pharma (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Pierre Fabre; Roche; Sun Pharma
 
Daniil Stroyakovskiy
Speakers' Bureau - AstraZeneca; BioCad; Bristol-Myers Squibb; Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Roche; Roche
 
Helen Gogas
Honoraria - Bristol-Myers Squibb; MSD Oncology; Pierre Fabre; Sanofi/Regeneron
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD Oncology; Pierre Fabre; Sanofi/Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Iovance Biotherapeutics (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD; Pfizer
 
Caroline Robert
Stock and Other Ownership Interests - RiboNexus
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Research Funding - Novartis (Inst)
 
Svetlana Protsenko
Honoraria - BIOCAD; Bristol-Myers Squibb; MSD; Roche
Speakers' Bureau - BIOCAD; Bristol-Myers Squibb; MSD; Roche
Research Funding - Amgen; BIOCAD; Bristol-Myers Squibb; MSD; Novartis; Roche
 
Rodrigo Perez Pereira
Speakers' Bureau - Bristol-Myers Squibb; Roche
Research Funding - AstraZeneca; Bayer; Bristol-Myers Squibb; MSD; Roche
 
Thomas Eigentler
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Novartis; Pierre Fabre; Sanofi/Regeneron
Speakers' Bureau - Almirall Hermal GmbH
 
Piotr Rutkowski
Honoraria - Bristol-Myers Squibb; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Amgen; Blueprint Medicines; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Speakers' Bureau - Novartis; Pfizer; Pierre Fabre
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Orphan Europe; Pierre Fabre
 
Lev V. Demidov
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Roche
Research Funding - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche
 
Natalia V. Zhukova
No Relationships to Disclose
 
Jacob Schachter
Consulting or Advisory Role - Bristol-Myers Squibb; MSD
 
Yibing Yan
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche/Genentech
 
Ivor Caro
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Christian Hertig
Employment - Roche
 
Cloris Xue
Employment - F. Hoffmann LaRoche
 
Lieke Kusters
Employment - Roche
Stock and Other Ownership Interests - F. Hoffmann LaRoche
Honoraria - Roche
 
Paolo Antonio Ascierto
Stock and Other Ownership Interests - PrimeVax
Consulting or Advisory Role - 4SC; Alkermes; Array BioPharma; AstraZeneca; Bio-AI Health; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Idera; Immunocore; Incyte; Italfarmaco; ITeos Therapeutics; Lunaphore Technologies; Medicenna; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Nouscom; Novartis; OncoSec; Pfizer; Pierre Fabre; Regeneron; Roche/Genentech; Sandoz; Sanofi; Seagen; Sun Pharma; Takis Biotech; Ultimovacs
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Karl D. Lewis
Honoraria - Array BioPharma; Iovance Biotherapeutics
Consulting or Advisory Role - Array BioPharma; Iovance Biotherapeutics; Merck; nektar; Regeneron; Roche; Sanofi
Research Funding - alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Kartos Therapeutics (Inst); Merck (Inst); Nektar (Inst); Neon Therapeutics (Inst); OncoSec (Inst); Regeneron (Inst); Replimune (Inst); Roche/Genentech (Inst); Seagen (Inst); Senhwa Biosciences (Inst); Ultimovacs (Inst)
Travel, Accommodations, Expenses - alkermes; Merck; Neon Therapeutics; Regeneron; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Regeneron; Roche/Genentech